Review
Open access
Oct 2026
KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine
ABSTRACT KRAS is one of the most frequently altered oncogenic drivers across human solid tumors and has long represented a central challenge in precision oncology. The clinical success of covalent KRAS G12C inhibitors has transformed a historically “undruggable” target into a tractable therapeutic class, but durable be...
Jia-Ying Cai, Yi-Min Wu, Xing Jia et al.
· MedComm · 0 citations